PLUVICTO™ Receives Positive Recommendations from CADTH and INESSS for Progressive PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
Health technology assessment (HTA) agencies reinforce the therapeutic value of PLUVICTO™ and need for new approaches to treat advanced prostate cancer Positive HTA recommendations for reimbursement are an important milestone… Read More


